Accepted for publication: Precision T cell correction platform for inborn errors of immunity
Our paper was accepted for publication and is available online ahead of print.
September 19, 2025
News: research and publications
Catch up on the latest news about what we’ve been up to and what’s happening at Haapaniemi Lab, including new job openings, research updates, new publications and team events.
Research and publications
Pre-print: Editing of ADA2 Point Mutation in Human Hematopoietic Stem Cells
Our newest paper is currently in pre-print and available on bioRxiv!
August 31, 2025
New publication: Heterozygous loss of MAP4K1 causes immune dysregulation by amplifying T cell responses
We’re excited to present our newest paper (pre-proof) in the Journal of Allergy and Clinical Immunology!
July 31, 2025
Exciting news: Haapaniemi Group extended at NCMBM
Our work at NCMBM will continue for another 4 years!
June 1, 2025
Preprint: T cell correction pipeline for Inborn Errors of Immunity
We’re excited to present our newest paper, currently in preprint!
September 10, 2024
We have a new article in the STAR Protocols journal
We’re excited to present our newest publication, published in the STAR Protocols journal in December 2023.
December 31, 2023
Curing rare immunodeficiency diseases with gene editing
We are working on editing defective genes with CRISPR, a method we hope can cure all primary immunodeficiency diseases in the future. The technique we
February 13, 2023
Emma was featured in the Apollon magazine
Our group leader was interviewed in Apollon, the award-winning magazine published by the University of Oslo.
December 16, 2022
PRIMA, a new Center of Excellence received funding!
We are very proud to be part of Precision Immunotherapy Alliance “PRIMA”, a new Center of Excellence recently founded by The Research Council of Norway!
September 30, 2022
We represented NCMM in an Aftenposten article
Aftenposten run a focused life science collection. Our laboratory was featured as representatives of NCMM in an article about new therapies for serious diseases in
July 3, 2022